ALX Oncology (ALXO) vs BridgeBio Oncology Therapeutics (BBOT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ALX Oncology (ALXO) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 25.9% versus a loss of 85.4%. BridgeBio Oncology Therapeutics is the larger company by market cap ($145.3 million vs $137.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | BBOT |
|---|---|---|
| Share price | $1.06 | $1.81 |
| Market cap | $137.03M | $145.25M |
| 1-day change | +3.92% | -2.69% |
| YTD return | -6.19% | -85.54% |
| 1-year return | -25.87% | -85.39% |
| 5-year return | -96.84% | — |
| P/E ratio (TTM) | — | 3.42 |
| EPS (TTM) | $-0.87 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-101.69M | $-134.04M |
| 52-week high | $2.66 | $14.87 |
| 52-week low | $0.862 | $1.79 |
| Distance from 52-week high | -60.15% | -87.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +333.96% | +1060.22% |
| Average volume | 1.19M | 631.56K |
| Shares outstanding | 129.27M | 80.25M |
| Employees | 49 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed BBOT by 59.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
ALXO vs BBOT FAQ
Which is bigger, ALX Oncology or BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $145.25M compared with $137.03M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or BBOT?
ALXO returned -25.87% over the past 12 months, compared with -85.39% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and BridgeBio Oncology Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.